Objectives: The aim of this study was to appraise 1-year outcomes after percutaneous
treatment of long femoropopliteal artery disease using paclitaxel-coated balloons …

Objectives: The aim of this study was to appraise 2-year outcomes after percutaneous
transluminal angioplasty of long femoropopliteal artery disease using paclitaxel-coated …

Objectives: This study aimed to appraise 2-year outcomes after percutaneous treatment of
femoropopliteal artery disease with paclitaxel-eluting balloons. Background: Percutaneous …

Objectives This study evaluated the 12-month safety and effectiveness of a paclitaxel drug-
coated balloon for treatment of intermittent claudication or rest pain in subjects with …

Background So far only 1-year data have been reported for direct comparisons of paclitaxel-
coated balloons (PCBs) using different coating technologies. Objectives The aim of this …

Background The treatment of peripheral artery disease with percutaneous transluminal
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …

Abstract Purpose of the Review Percutaneous transluminal angioplasty is an established
form of therapy for femoropopliteal artery disease. Currently, percutaneous transluminal …

Background: Numerous studies have reported favorable outcomes using drug-coated
balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial …

Objectives To assess the safety and effectiveness of the Stellarex™ drug‐coated
angioplasty balloon (DCB) to inhibit restenosis in the superficial femoral and/or popliteal …

Background—In disease of the femoropopliteal artery, paclitaxel-coated balloon (PCB)
therapy improved angiographic outcomes as compared with uncoated balloon (UCB) …